Your browser doesn't support javascript.
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Barlow, Ashley; Landolf, Kaitlin M; Barlow, Brooke; Yeung, Siu Yan Amy; Heavner, Jason J; Claassen, Cassidy W; Heavner, Mojdeh S.
  • Barlow A; Department of Pharmacy, University of Maryland Medical Center, Baltimore, Maryland.
  • Landolf KM; Department of Pharmacy, University of Maryland Medical Center, Baltimore, Maryland.
  • Barlow B; Department of Pharmacy, University of Kentucky Healthcare, Lexington, Kentucky.
  • Yeung SYA; Department of Pharmacy, University of Maryland Medical Center, Baltimore, Maryland.
  • Heavner JJ; University of Maryland Baltimore Washington Medical Center, Glen Burnie, Maryland.
  • Claassen CW; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.
  • Heavner MS; Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, Maryland.
Pharmacotherapy ; 40(5): 416-437, 2020 05.
Article in English | MEDLINE | ID: covidwho-1449937
ABSTRACT
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into an emergent global pandemic. Coronavirus disease 2019 (COVID-19) can manifest on a spectrum of illness from mild disease to severe respiratory failure requiring intensive care unit admission. As the incidence continues to rise at a rapid pace, critical care teams are faced with challenging treatment decisions. There is currently no widely accepted standard of care in the pharmacologic management of patients with COVID-19. Urgent identification of potential treatment strategies is a priority. Therapies include novel agents available in clinical trials or through compassionate use, and other drugs, repurposed antiviral and immunomodulating therapies. Many have demonstrated in vitro or in vivo potential against other viruses that are similar to SARS-CoV-2. Critically ill patients with COVID-19 have additional considerations related to adjustments for organ impairment and renal replacement therapies, complex lists of concurrent medications, limitations with drug administration and compatibility, and unique toxicities that should be evaluated when utilizing these therapies. The purpose of this review is to summarize practical considerations for pharmacotherapy in patients with COVID-19, with the intent of serving as a resource for health care providers at the forefront of clinical care during this pandemic.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Immunomodulation Type of study: Experimental Studies / Observational study / Prognostic study Language: English Journal: Pharmacotherapy Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Immunomodulation Type of study: Experimental Studies / Observational study / Prognostic study Language: English Journal: Pharmacotherapy Year: 2020 Document Type: Article